- Home
- BIIB vs UAL Comparison
BIIB vs UAL Comparison
Compare BIIB & UAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- UAL
- Stock Information
- Founded
- BIIB 1978
- UAL 1934
- Country
- BIIB United States
- UAL United States
- Employees
- BIIB N/A
- UAL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- UAL Air Freight/Delivery Services
- Sector
- BIIB Health Care
- UAL Consumer Discretionary
- Exchange
- BIIB Nasdaq
- UAL Nasdaq
- Market Cap
- BIIB 18.7B
- UAL 32.0B
- IPO Year
- BIIB 1991
- UAL N/A
- Fundamental
- Price
- BIIB $151.22
- UAL $95.46
- Analyst Decision
- BIIB Buy
- UAL Strong Buy
- Analyst Count
- BIIB 22
- UAL 14
- Target Price
- BIIB $174.11
- UAL $125.77
- AVG Volume (30 Days)
- BIIB 1.5M
- UAL 7.1M
- Earning Date
- BIIB 10-30-2025
- UAL 10-15-2025
- Dividend Yield
- BIIB N/A
- UAL N/A
- EPS Growth
- BIIB N/A
- UAL 20.30
- EPS
- BIIB 10.97
- UAL 9.99
- Revenue
- BIIB $10,065,900,000.00
- UAL $58,369,000,000.00
- Revenue This Year
- BIIB $2.03
- UAL $4.73
- Revenue Next Year
- BIIB N/A
- UAL $7.73
- P/E Ratio
- BIIB $14.06
- UAL $9.42
- Revenue Growth
- BIIB 4.77
- UAL 4.24
- 52 Week Low
- BIIB $110.04
- UAL $52.00
- 52 Week High
- BIIB $179.48
- UAL $116.00
- Technical
- Relative Strength Index (RSI)
- BIIB 54.91
- UAL 45.06
- Support Level
- BIIB $138.00
- UAL $92.34
- Resistance Level
- BIIB $151.91
- UAL $100.69
- Average True Range (ATR)
- BIIB 4.70
- UAL 3.74
- MACD
- BIIB 0.10
- UAL -0.49
- Stochastic Oscillator
- BIIB 68.59
- UAL 20.27
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About UAL United Airlines Holdings Inc.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.